What is Pentara?
Established in 2001, Pentara operates as a high-authority clinical research organization, providing a comprehensive suite of services that includes study design, biostatistics, and regulatory support. The company distinguishes itself through deep technical expertise in data management and statistical consulting, specifically targeting the complex requirements of neurodegenerative disease research, such as Alzheimer's. By serving a broad spectrum of pharmaceutical and biotechnology clients, Pentara ensures the integrity and quality of clinical trial data, acting as a critical partner in the drug development lifecycle. Their commitment to advancing medical research through rigorous statistical methodology has solidified their reputation as a leader in the CRO sector.
How much funding has Pentara raised?
Pentara has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Pentara
PPP
Public-Private Partnership
What's next for Pentara?
With this recent strategic financing, Pentara is poised to accelerate its growth trajectory and deepen its impact on the global medical research ecosystem. The infusion of capital will likely be directed toward scaling its biostatistics and clinical programming capabilities, allowing the firm to handle increasingly complex trial designs. As the demand for high-quality, data-driven clinical insights continues to rise, Pentara's focus on neurodegenerative disease research positions it to capture significant market share. Future strategic initiatives will likely involve enhancing their regulatory support infrastructure and expanding their footprint within the biotechnology sector, ensuring they remain at the forefront of medical innovation and clinical excellence.
See full Pentara company page
